A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients

Anaesthesia

Volumn 63, Issue 1, 2008, Pages 52-64

  Biccard, B M ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANESTHESIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; REVIEW; SURVIVAL; WITHDRAWAL SYNDROME;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; DRUG MONITORING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 36949023522     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2007.05264.x     Document Type: Review

References (93)

1. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of Vascular Surgery 2004 39 : 967 75 discussion 975 6.
2. Kapoor AS, Kanji H, Buckingham J, Devereaux PJ, McAlister FA. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. British Medical Journal 2006 333 : 1149 56.
3. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006 105 : 1260 72 quiz 1289 90.
4. Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Annals of Internal Medicine 1997 127 : 313 28.
5. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. British Medical Journal 2005 331 : 313 21.
6. Wiesbauer F, Schlager O, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. Anesthesia and Analgesia 2007 104 : 27 41.
7. Feringa HH, Bax JJ, Boersma E, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation 2006 114 : I344 9.
8. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. New England Journal of Medicine 1996 335 : 1713 20.
9. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. New England Journal of Medicine 1999 341 : 1789 94.
10. Biccard BM, Sear JW, Foex P. Acute peri-operative beta blockade in intermediate-risk patients. Anaesthesia 2006 61 : 924 31.
11. Giles JW, Sear JW, Foex P. Effect of chronic beta-blockade on peri-operative outcome in patients undergoing non-cardiac surgery: an analysis of observational and case control studies. Anaesthesia 2004 59 : 574 83.
12. Howard-Alpe GM, Sear JW, Foex P. Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers. British Journal of Anaesthesia 2006 97 : 758 69.
13. Dickson BC, Gotlieb AI. Towards understanding acute destabilization of vulnerable atherosclerotic plaques. Cardiovascular Pathology 2003 12 : 237 48.
14. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
15. Boushra NN, Muntazar M. Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives. Canadian Journal of Anaesthesia 2006 53 : 1126 47.
16. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001 104 : 365 72.
17. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. American Journal of Cardiology 2007 99 : 732 8.
18. Chandrasekar B, Mummidi S, Mahimainathan L, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. Journal of Biological Chemistry 2006 281 : 15099 109.
19. Dunkelgrun M, Schouten O, Feringa HH, Vidakovic R, Poldermans D. Beneficial effects of statins on perioperative cardiovascular outcome. Current Opinion in Anaesthesiology 2006 19 : 418 22.
20. Libby P, Sasiela W. Plaque stabilization: Can we turn theory into evidence? American Journal of Cardiology 2006 98 : 26P 33P.
21. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. American Journal of Cardiology 2005 96 : 24F 33F.
22. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New England Journal of Medicine 1994 331 : 417 24.
23. Li JJ, Li YS, Chu JM, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clinica Chimica Acta 2006 366 : 269 73.
24. Mulder DJ, van Haelst PL, Wobbes MH, et al. The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovascular Drugs and Therapy 2007 21 : 91 7.
25. Taneva E, Borucki K, Wiens L, et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. American Journal of Cardiology 2006 97 : 1002 6.
26. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002 106 : 1447 52.
27. Morawietz H, Erbs S, Holtz J, et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 2006 114 : I296 301.
28. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Journal of the American Medical Association 2004 292 : 1307 16.
29. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004 350 : 1495 504.
30. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Journal of Thrombosis and Haemostasis 2003 90 : 476 82.
31. Thomas MK, Narang D, Lakshmy R, et al. Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients 'on' and 'off' atorvastatin for short time intervals. Cardiovascular Drugs and Therapy 2006 20 : 37 44.
32. Alber HF, Frick M, Suessenbacher A, et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease - a randomized, placebo-controlled study. American Heart Journal 2006 151 : 139.
33. Dupuis J, Tardif JC, Rouleau JL, et al. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). American Journal of Cardiology 2005 96 : 1207 13.
34. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999 99 : 3227 33.
35. Karatzis E, Lekakis J, Papamichael C, et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. International Journal of Cardiology 2005 101 : 65 70.
36. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circulation Research, 2003 : 93 : e 98 103.
37. Lai WT, Lee KT, Chu CS, et al. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. International Journal of Cardiology 2005 98 : 459 64.
38. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001 103 : 926 33.
39. Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. Journal of the American College of Cardiology 2006 48 : 1560 6.
40. Molloy KJ, Thompson MM, Schwalbe EC, et al. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. American Journal of Cardiology 2004 94 : 144 6.
41. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clinica Chimica Acta 2003 338 : 17 24.
42. Link A, Ayadhi T, Bohm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. European Heart Journal 2006 27 : 2945 55.
43. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology 2005 46 : 1417 24.
44. Kanadasi M, Cayli M, Demirtas M, et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels 2006 21 : 291 7.
45. Huang CY, Wu TC, Lin WT, et al. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. European Journal of Clinical Investigation 2006 36 : 76 84.
46. Zhou T, Zhou SH, Qi SS, et al. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clinica Chimica Acta 2006 368 : 168 72.
47. Bruni F, Pasqui AL, Pastorelli M, et al. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. International Journal of Cardiology 2004 95 : 269 74.
48. Atalar E, Coskun S, Haznedaroglu IC, et al. Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes. Cardiovascular Drugs and Therapy 2005 19 : 177 81.
49. Yip HK, Youssef AA, Chua S, et al. Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting. International Heart Journal 2006 47 : 501 9.
50. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994 344 : 1383 9.
51. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 1996 335 : 1001 9.
52. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 1998 339 : 1349 57.
53. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995 333 : 1301 7.
54. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association 1998 279 : 1615 22.
55. MRC/ BHF. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
56. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 : 1149 58.
57. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? American Journal of Cardiology 2006 98 : 18P 25P.
58. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
59. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. Journal of the American College of Cardiology 2005 46 : 1855 62.
60. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. Journal of the American Medical Association 2007 297 : 499 508.
61. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005 352 : 1425 35.
62. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association 2005 294 : 2437 45.
63. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? American Journal of Cardiology 2006 97 : 33A 41A.
64. McGowan MP. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004 110 : 2333 5.
65. Wayhs R, Zelinger A, Raggi P. High coronary artery calcium scores pose an extremely elevated risk for hard events. Journal of the American College of Cardiology 2002 39 : 225 30.
66. Toutouzas K, Drakopoulou M, Markou V, et al. Correlation of systemic inflammation with local inflammatory activity in non-culprit lesions: Beneficial effect of statins. International Journal of Cardiology 2007 119 : 368 73.
67. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. Journal of the American Medical Association 2006 295 : 2046 56.
68. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 2006 166 : 1814 21.
69. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Journal of the American Medical Association 2001 285 : 1711 8.
70. Kayikcioglu M, Can L, Kultursay H, Payzin S, Turkoglu C. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiologica 2002 57 : 295 302.
71. Thompson PL, Meredith I, Amerena J, et al. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. American Heart Journal 2004 148 : e2.
72. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Journal of the American Medical Association 2002 287 : 3215 22.
73. Den Hartog FR, Van Kalmthout PM, Van Loenhout TT, et al. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial. International Journal of Clinical Practice 2001 55 : 300 4.
74. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. American Journal of Cardiology 2005 96 : 611 6.
75. Saab FA, Eagle KA, Kline-Rogers E, et al. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. American Journal of Cardiology 2004 94 : 1166 8.
76. Wright RS, Bybee K, Miller WL, et al. Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. International Journal of Cardiology 2006 108 : 314 9.
77. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. American Heart Journal 2001 141 : 148 53.
78. Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. Circulation 1986 73 : 1281 90.
79. Lenderink T, Boersma E, Gitt AK, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. European Heart Journal 2006 27 : 1799 804.
80. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST- segment elevation myocardial infarction: national registry of myocardial infarction. Archives of International Medicine 2004 164 : 2162 8.
81. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002 105 : 1446 52.
82. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003 107 : e27.
83. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart 2007 93 : 914 21.
84. Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007 115 : 2398 409.
85. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine 2005 352 : 20 8.
86. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003 108 : 1560 6.
87. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid × lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006 113 : 1406 14.
88. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. Journal of the American College of Cardiology 2005 45 : 1594 9.
89. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001 104 : 1477 82.
90. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004 110 : 674 8.
91. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. European Heart Journal 2004 25 : 1822 8.
92. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. European Heart Journal 1999 20 : 58 69.
93. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003 107 : 1750 6.